Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
about
Aripiprazole for autism spectrum disorders (ASD)Aripiprazole for autism spectrum disorders (ASD)Aggression in autism spectrum disorder: presentation and treatment optionsAripiprazole for treating irritability in children & adolescents with autism: A systematic reviewCognitive-behavioral therapy for anxiety in children with high-functioning autism: a meta-analysisAripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-AnalysisPharmacotherapy to control behavioral symptoms in children with autismPharmacological management in children and adolescents with pervasive developmental disorder.Aripiprazole in autism spectrum disorders and fragile X syndrome.Retrospective case series of aripiprazole augmentation in pervasive developmental disordersBrief report: an open-label study of the neurosteroid pregnenolone in adults with autism spectrum disorderAripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years.Focus on aripiprazole: a review of its use in child and adolescent psychiatryEvidence-based recommendations for monitoring safety of second generation antipsychotics in children and youthEfficacy and safety of aripiprazole in child and adolescent patientsThe effects of aripiprazole on electrocardiography in children with pervasive developmental disorders.Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.Prolactin serum concentrations during aripiprazole treatment in youth.Aripiprazole for the treatment of irritability associated with autism.Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.The use of antipsychotics in preschoolers: a veto or a sensible last option?What's in the pipeline? Drugs in development for autism spectrum disorder.Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder.Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.Pharmacogenomic medicine in autism: challenges and opportunities.Asperger's syndrome: diagnosis, comorbidity and therapy.A failure to confirm the effectiveness of a brief group psychoeducational program for mothers of children with high-functioning pervasive developmental disorders: a randomized controlled pilot trial.Aripiprazole Improved Obsessive Compulsive Symptoms in Asperger's Disorder.Repeated aripiprazole treatment causes dopamine D2 receptor up-regulation and dopamine supersensitivity in young rats.Paliperidone for irritability in adolescents and young adults with autistic disorder.A prospective open-label study of aripiprazole in fragile X syndrome.Aripiprazole in the treatment of challenging behaviour in adults with autism spectrum disorder.
P2860
Q24197830-B84B4CAE-1C92-4A93-9EBE-610D1E03C625Q26471439-CBB8FE77-C905-471E-9ACC-9257D865CA3AQ26744346-FE38212E-01C8-407E-A839-4DA21240E5CCQ26784199-52F9C9C5-1BBD-424C-8A24-740FBB0FFCBBQ26862584-408FAA04-2633-4396-8D40-E16DD8C8D7A7Q28073540-7BD97A41-37BE-4FA1-8452-5B70EFA7931FQ28265801-4EF03DE3-83AF-41D6-B27E-81467D95308FQ33521748-83AF5998-F226-45A1-80F2-AA06B948999AQ34025492-F401F27C-28B5-4F53-AE44-984E00B5563DQ34165087-D9E3122B-66F9-4E8E-A8C9-BB9EFC817ABBQ34325264-926747A2-151C-4699-A3CE-3034A95232E3Q34597411-61B79691-C885-4705-B4D7-840921416057Q34611306-720E16FE-B82B-4012-B0B5-343CC7AC3F88Q35128405-6AF2DF44-34C7-4704-9368-94D17D490095Q36075828-8B1CE745-F61A-42B0-BB92-DECC314BB700Q36321595-6272A47D-67AA-4D9D-9387-1644304ECEF1Q36443014-35DD41AF-EC5C-4C49-A10A-557A9B5DE5A2Q36853126-D28E94C0-C1C4-4259-9BA4-2F0E7E84660CQ37835845-244A7F21-62B3-4920-A0DA-34D852E22C60Q38095762-48A30924-DEF3-4EC6-B8D1-60C04A8A7E80Q38180865-81CB24B4-7513-46A3-9FC6-F899864EF38DQ38193069-400C3ECE-E5CC-48CF-9B5E-A46974C8BE75Q38237334-D9F96A22-C5CC-42B1-9967-61F93F90933FQ38268023-3A7182E3-5A26-40BD-ABD5-864011133C90Q38270928-164DC256-C2E2-412B-BE7C-792BB163765AQ38345718-683D77E8-350B-4667-9914-1CFAACF3EA32Q41908496-0AA105E7-523D-4DA5-BEE4-BC9268D8F689Q43235601-563C7513-58EF-4C43-BFED-32A759A0D430Q45377706-6B3D83E4-FC8C-4B9E-86B7-3C7AB79F34FBQ47291177-B358988E-4F52-4EB8-AC2E-E9FDE1392A03Q47293259-32EE8185-D315-4AD0-91BB-4965B8C2F0C4Q47850608-3BBAD19C-BD42-41BC-8EA1-49A7D4415D10
P2860
Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Aripiprazole in pervasive deve ...... prospective, open-label study.
@ast
Aripiprazole in pervasive deve ...... prospective, open-label study.
@en
type
label
Aripiprazole in pervasive deve ...... prospective, open-label study.
@ast
Aripiprazole in pervasive deve ...... prospective, open-label study.
@en
prefLabel
Aripiprazole in pervasive deve ...... prospective, open-label study.
@ast
Aripiprazole in pervasive deve ...... prospective, open-label study.
@en
P2093
P2860
P356
P1476
Aripiprazole in pervasive deve ...... prospective, open-label study.
@en
P2093
Arlene E Kohn
Craig A Erickson
David J Posey
Jonathan T Diener
Kimberly A Stigler
P2860
P304
P356
10.1089/CAP.2008.093
P577
2009-06-01T00:00:00Z